Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
Year: 2013
Type: report
Abstract: Background: Warfarin has been used as the only oral anticoagulant for over 50 years in patients with atrial fi brillation.Recently new oral anticoagulants like dabigatran, rivaroxaban and apixaban have been developed for this indication.We compared these new oral anticoagulants with each other and with warfarin with respect to effi cacy and cost-effectiveness for patients with atrial fi brillation and moderate or high risk of stroke.Main fi ndings: • The new oral anticoagulants reported statistically signifi cant reductions of intracranial bleeding compared to warfarin.For the outcomes all-cause mortality, ischemic stroke, gastrointestinal bleeding and myocardial infarction, results were inconclusive.The quality of evidence for the outcomes was generally regarded as low or very low.• Only one large randomised controlled trial presently exists for each of these three new oral anticoagulants, all compared to warfarin.This necessitated modelling through indirect comparisons.• Apixaban 5 mg x 2, dabigatran 150 mg x 2 and rivaroxaban 20 mg x 1 all seems to be cost-effective when each are compared to warfarin for patients with atrial fi brillation at medium and high risk of Effi cacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fi brillation Report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services) No 5-2013 Health Technology Assessment (continued) Norwegian Knowledge Centre for the Health Services (Kunnskapssenteret)
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2785399770